T3 Companies LLC Purchases Shares of 945,000 VYNE Therapeutics Inc. $VYNE

T3 Companies LLC purchased a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 945,000 shares of the company’s stock, valued at approximately $548,000. T3 Companies LLC owned approximately 2.84% of VYNE Therapeutics as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of VYNE. Baker BROS. Advisors LP purchased a new stake in VYNE Therapeutics during the third quarter valued at approximately $285,000. Adage Capital Partners GP L.L.C. grew its holdings in VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares during the last quarter. Shay Capital LLC purchased a new position in VYNE Therapeutics in the third quarter worth $165,000. Geode Capital Management LLC increased its position in shares of VYNE Therapeutics by 64.2% during the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock worth $131,000 after purchasing an additional 88,030 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of VYNE Therapeutics during the third quarter worth $74,000. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Price Performance

Shares of VYNE stock opened at $0.66 on Thursday. The business has a fifty day moving average of $0.65 and a 200 day moving average of $0.58. VYNE Therapeutics Inc. has a 1 year low of $0.28 and a 1 year high of $1.96. The firm has a market capitalization of $21.97 million, a price-to-earnings ratio of -1.73 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.10. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.20 million. As a group, equities research analysts expect that VYNE Therapeutics Inc. will post -1.1 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, VYNE Therapeutics currently has a consensus rating of “Reduce”.

VYNE Therapeutics Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.